Alkermes
advancing fast to market opportunity in platinum resistant ovarian cancer advance discussions on registration plans with regulatory agencies initiate study with intravenous in combination with complete enrollment subcutaneous dose expansion cohort initiated ongoing studies designed to accumulate additional data artistry intravenous phase artistry subcutaneous phase artistry tumor phase ion head and neck phase | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
75 of 144
Related slides by other companies
Exscientia
Results
March 2024
advancing multiple programmes in | Exscientia
Exscientia
Results
November 2023
pipeline advancing to the clinic | Exscientia
argenx SE
Investor Conference
January 2024
phase present significant commercial opportunities | argenx SE
Exscientia
Investor Day
January 2024
pipeline advancing to the clinic | Exscientia
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io